Latest Breaking News On - பீட்டர் டோவர்டீ நிறுவனம் ஆஃப் தொற்று - Page 1 : comparemela.com

A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint venture of the University of Melbourne and Royal Melbourne Hospital, has shown that an anti-parasitic drug already available around the world kills the virus within 48 hours. Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-19 spectrum anti-viral activity in vitro, is an inhibitor of the causative virus. The use of Ivermectin to combat COVID-19 depends on pre-clinical testing and clinical trials, with funding urgently required to progress the work.

South australiaKylie wagstaffDavid jansUniversity of melbourneDoherty instituteImmunity doherty instituteMonash biomedicine discovery instituteVictorian infectious diseases reference laboratoryAntiviral researchPeter doherty institute of infectionPeter doherty instituteRoyal melbourne hospitalMonash university ledMelbourne hospitalSenior medical scientistProfessor david jans